Ligachem Bio and Ono Pharmaceutical accelerate joint ADC research, receiving follow-up milestones

CAR-T Digest - August 2020

27 February 2026: Ligachem Bio and Ono Pharmaceutical accelerate joint ADC research, receiving follow-up milestones

Ligachem Biosciences has announced that it will receive additional development milestone payments from Ono Pharmaceutical as their joint research on antibody-drug conjugates (ADCs) continues to advance. The milestone follows recent progress in their collaboration focused on Ligachem Bio’s proprietary ADC platform, ConjuAll™
The update comes only about six weeks after the partners reported a previous milestone in early January 2026, highlighting the rapid pace of development within the program, their collaboration, originally established in October 2024, aims to jointly discover and develop ADC candidates using the ConjuAll™ technology platform
Since the first target was designated in March 2025, the partnership has steadily progressed along its development roadmap, achieving consecutive milestones in both January and February 2026. This rapid succession of achievements underscores the operational efficiency of the collaboration between Ligachem Bio and Ono Pharmaceutical
The continued progress in a short timeframe also highlights the stability and scalability of Ligachem Bio’s ConjuAll™ ADC platform, which appears capable of meeting the rigorous standards required by global pharmaceutical partners, financial details of the milestone payments remain confidential under the agreement between the two companies